Zobrazeno 1 - 10
of 37
pro vyhledávání: ''
Autor:
Charles S. Kuzma, Harry P. Erba, Mark R. Litzow, Steven Coutre, Scott E. Smith, Richard Stone, Amy S. Ruppert, Allison M Booth, Nancy L. Bartlett, Jeremy S. Abramson, John C. Byrd, Jennifer A. Woyach, Jennifer R. Brown, Richard F. Little, Richard A. Larson, Sumithra J. Mandrekar, Wei Ding, Sreenivasa Nattam, Carolyn Owen, Danielle M. Brander
Publikováno v:
Leukemia
Ibrutinib has superior progression-free survival compared with bendamustine plus rituximab (BR) in older CLL patients, however, differences in treatment duration, six monthly BR cycles versus continuous ibrutinib, complicate adverse event (AE) compar
Autor:
Angela Dispenzieri, Giampaolo Merlini, Arun Kumar, Ashutosh D. Wechalekar, Heather Landau, Vaishali Sanchorawala, Kihyun Kim, Efstathios Kastritis, Raymond L. Comenzo, Guohui Liu, Deborah Berg, Fiona Kwok, Stefan Schönland, Douglas V. Faller, Kenshi Suzuki
Publikováno v:
Leukemia
In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1–2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, d
Autor:
Zeev Estrov, Prithviraj Bose, Varsha Gandhi, Jan A. Burger, Xuemei Wang, Naveen Garg, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Philip A. Thompson, Ana Ayala, Hagop M. Kantarjian, Koji Sasaki, Keyur P. Patel, Tapan M. Kadia, Alessandra Ferrajoli, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Koichi Takahashi, Marina Konopleva, Wanda Lopez, Michael J. Keating, Wei Wang, William G. Wierda, Nitin Jain, Jeffrey L. Jorgensen, William Plunkett, Sa Wang
Publikováno v:
Leukemia. 35:3421-3429
Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mut
Autor:
Ben L. Sanford, Martin S. Tallman, Richard F. Schlenk, Lucas J. Huebner, Jürgen Krauter, Hartmut Döhner, Maria Teresa Voso, Hubert Serve, Andrew H. Wei, Jorge Sierra, Bruno C. Medeiros, Dietger Niederwieser, Arnold Ganser, Insa Gathmann, Miguel A. Sanz, Joseph Brandwein, Rebecca B. Klisovic, Sergio Amadori, Christian Thiede, Thomas W. Prior, Richard A. Larson, Theo de Witte, Konstanze Döhner, Kristina Laumann, Richard Stone, Clara D. Bloomfield, Frederick R. Appelbaum, Guido Marcucci, Gerhard Ehninger, Ilene Galinsky, Susan Geyer, Sumithra J. Mandrekar
Publikováno v:
Leukemia, 35, 9, pp. 2539-2551
Leukemia, 35, 2539-2551
Leukemia
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Leukemia, 35, 2539-2551
Leukemia
LEUKEMIA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Contains fulltext : 237748.pdf (Publisher’s version ) (Closed access) The prospective randomized, placebo-controlled CALGB 10603/RATIFY trial (Alliance) demonstrated a statistically significant overall survival benefit from the addition of midostau
Publikováno v:
Leukemia. 35:906-909
Publikováno v:
Leukemia. 34:682-696
The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by a point mutation mainly involving the tyrosine kinase domain (FLT
Autor:
Asher Chanan-Khan, Olga Samoilova, Charles Phelps, Michelle Mahler, Javier Loscertales, Dirceu Villa Villa, Ann Janssens, Andre Goy, M. Salman, Simon Rule, Claes Karlsson, Miguel A. Pavlovsky, Graeme Fraser, Angela Howes, Alexander Pristupa, Steven Sun, Marie-Sarah Dilhuydy, Abraham Avigdor, Paula Cramer, Panagiotis Panagiotidis, Nancy L. Bartlett, Sriram Balasubramanian, Jiří Mayer, Fatih Demirkan, R. Santucci Silva, Sebastian Grosicki, Halyna Pylypenko, Michael Hallek
Publikováno v:
Leukemia
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Ov
Autor:
Li Chen, Di Wu, Hongxiang Wang, Yu Hu, Wenxiang Ren, Lei Chen, Fei Gao, Qiubai Li, Lei Li, Weiqun Chen, Yulin Cao, Qijie Ran, Wenlan Chen, Fang Dong, Jianming Yu, Zhichao Chen, Robert Peter Gale, Qiaomei Liu, Wenjuan He
Publikováno v:
Leukemia
We studied admission and dynamic demographic, hematological and biochemical co-variates in 1449 hospitalized subjects with coronavirus infectious disease-2019 (COVID-19) in five hospitals in Wuhan, Hubei province, China. We identified two admission c
Autor:
Karen Francoeur, Matthew S. Davids, Oreofe O. Odejide, Josie Montegaard, Jon E. Arnason, Mikaela McDonough, David C. Fisher, Brandon Lee, Svitlana Tyekucheva, Jennifer R. Brown, Philippe Armand, John Hanna
Publikováno v:
Leukemia
Fludarabine, cyclophosphamide, and rituximab (FCR) is highly effective initial therapy for younger patients with chronic lymphocytic leukemia (CLL); however, most eventually relapse. Duvelisib is a delta/gamma PI3K inhibitor approved for relapsed/ref
Autor:
Marika Porrazzo, Francesca Romana Mauro, Silvia Baroncelli, Clementina Maria Galluzzo, Giuseppe Gentile, Candida Vitale, Diana Giannarelli, Marta Coscia, Costantino Riemma, Serena Rosati, Massimo Gentile, Sara Raponi, Alessandra Micozzi, Sara Pepe, Livio Trentin, Andrea Visentin
Publikováno v:
Leukemia. 35(3)
Pneumococcal (PC) vaccination is recommended for patients with chronic lymphocytic leukemia (CLL). However, response to vaccines has been investigated in a small series of CLL patients. We analyzed the antibody response and outcomes of 112 CLL patien